GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Float Percentage Of Total Shares Outstanding

Heidelberg Pharma AG (XTER:HPHA) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 20, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Heidelberg Pharma AG's float shares is 0.00 Mil. Heidelberg Pharma AG's total shares outstanding is 46.60 Mil. Heidelberg Pharma AG's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Heidelberg Pharma AG's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Heidelberg Pharma AG's Institutional Ownership is 1.21%.

Heidelberg Pharma AG Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Heidelberg Pharma AG's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/46.60
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG (XTER:HPHA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
XTER:MDG1 XTER:T5O OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX ALNY OCSE:GMAB BGNE BMRN INCY TECH UTHR RPRX
Traded in Other Exchanges
HPHA:Germany HPHA:Germany HPHA:Germany
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Website
https://www.heidelberg-pharma.com
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines